Cyclerion Therapeutics is a clinical-stage biopharmaceutical company applying neurological insights to discover, develop, and commercialize innovative medicines for people with serious diseases of the central nervous system (CNS). Lead programs include CY6463, a pioneering CNS-penetrant sGC stimulator in clinical development for Alzheimer's Disease with Vascular pathology (ADv), Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS), and Cognitive Impairment Associated with Schizophrenia (CIAS). Cyclerion is also advancing CY3018, a next-generation sGC stimulator.